• Users Online: 401
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 15  |  Issue : 1  |  Page : 12-15

Role of intravenous iron sucrose in comparison to oral ferrous sulfate for prophylaxis of anemia in pregnant women

Department of Obstetrics and Gynecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra, India

Correspondence Address:
Dr. Nanda Vinayak
Associate Professor, Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdmimsu.jdmimsu_5_20

Rights and Permissions

Purpose: The aim of our study is to compare intravenous (IV) iron sucrose with ferrous sulfate for prophylactic iron therapy in pregnancy in terms of hemoglobin percent (Hb%) rise. Materials and Methods: One hundred and fifty-four pregnant women fulfilling the inclusion criteria, with Hb >10gm/dl, between 20 and 24 weeks were selected and divided into two groups, 77 each. Group A was allotted to use three doses of iron sucrose, each dose 200 mg in 100 ml normal saline as infusion over 15–20 min at 20–24, 25–28, and 29–32 weeks, respectively, and Group B was allotted to use oral ferrous sulfate 200 mg tablet once daily at bed time. All pregnant women were followed till 32 weeks. Hb% was estimated for both the groups at 20–24 weeks, 25–28 weeks, and 29–32 weeks, and statistical analysis was carried out using the Chi-square test, Student's paired, and unpaired t-test with the SPSS software version 24.0 and Graph Pad Prism 7.0 version, and P < 0.05 is considered as level of statistical significance. Results: Mean Hb% at 20–24 weeks in patients of Group A was 11.11 ± 0.89, and in Group B, it was 11.04 ± 0.80; mean Hb% at 29–32 weeks in patients of Group A was 12.39 ± 0.99, and in Group B, it was 12.23 ± 0.89. Conclusions: IV iron sucrose can be used as prophylaxis for anemia in pregnant women as it requires less follow-up and causes a rapid increase in hemoglobin.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal